Michelle M. Kittleson, MD, PhD, and Nasrien E. Ibrahim, MD, will discuss how recent trial results can be leveraged to save lives with angiotensin receptor-neprilysin inhibition and SGLT2 inhibitors. The session begins at 8:00 ET.
Up next: New agents poised to transform management of heart failure
